Table 1.
Biomarker results
| Assay (reference range) | Initial test | +4 Months | +12 Months |
+19 Months |
+24 Months |
+27 Months |
|---|---|---|---|---|---|---|
| post bortezomib | post bortezomib | pre-transplantation | post-transplantation | |||
| CH50 (30-90 U/ml) | ND | 17 | 47 | 54 | 57 | 72 |
| AP functional assay (50% to 130%) | 0.1∗ | 0.2 | 99 | 101 | 96 | 95 |
| Hemolytic assay (<0.3%) | 0 | 0 | 0 | 0 | 0 | 0 |
| FH autoantibody (<1:50+) | 1:400+ | 1:200+ | <1:50+ | <1:50+ | <1:50+ | <1:50+ |
| FB autoantibody | Neg | Neg | Neg | Neg | Neg | Neg |
| IFE (<7.5%) | 23.3 | 25.4 | 2.9 | 5 | 4.7 | 6.1 |
| C3Nef | Neg | Neg | Neg | Neg | Neg | Neg |
| C4Nef | Neg | Neg | Neg | Neg | Neg | Neg |
| C3 (0.9-1.8 g/l) | 0.4 | 0.4 | 1.6 | 1.7 | 1.5 | 1.5 |
| C4 (0.15-0.57 g/l) | 0.28 | ND | ND | 0.4 | ND | ND |
| C3d (<0.7 mg/l) | ND | 0.86 | 0.1 | ND | ND | ND |
| C3c (<1.5mg/l) | ND | ND | 0.58 | 1.2 | 1.4 | 0.9 |
| FB (22-50 mg/dl) | 13.7 | 20.8 | 29.9 | 35.4 | 31.7 | 30.4 |
| Ba (<1.2 mg/l) | ND | 12.5 | 3.5 | 3.5 | 3.1 | 1.3 |
| Bb (<2.2 mg/l) | 3.3 | 5.6 | 0.6 | 1.2 | 1.1 | 0.8 |
| C5 (10-21 mg/dl) | 16.3 | 18.9 | 21.5 | 21.3 | 18.1 | 18.2 |
| Properdin (10-33 mg/l) | 9.0 | 13.9 | 15.8 | 16.4 | 18.8 | 16.6 |
| sC5b-9 (<0.3 mg/l) | 0.48 | 0.37 | 0.2 | 0.22 | 0.21 | 0.29 |
| FH (45-80 mg/l) | ND | 71 | 63 | 70 | ND | 72 |
| FI (16-40 mg/l) | ND | ND | ND | ND | ND | 34.6 |
AP, alternate pathway; C3Nef, C3 nephritic factor; C4Nef, C4 nephritic factor; CH50, complement hemolytic activity 50%; FB, factor B; FH, factor H; FI, factor I; Ba, factor Ba; Bb, factor Bb; Neg, negative; ND, not done;
∗
Abnormal results in italics.